
    
      The purpose of this study is to determine the safety and the efficacy of the combination of
      the drugs TH-302 and sunitinib in Treatment-na√Øve patients with well- and
      moderately-differentiated metastatic Pancreatic Neuroendocrine Tumours (pNET).
    
  